share_log

PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs

PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs

PavMed, 清醒診斷暫停一些開發計劃, 宣布裁員
Benzinga Real-time News ·  2023/01/18 06:27
  • PAVmed Inc (NASDAQ:PAVM), its majority-owned subsidiaries Lucid Diagnostics Inc (NASDAQ:LUCD), and Veris Health Inc provided a strategic business update outlining near-term strategic priorities and resource reallocation.
  • The companies will prioritize near-term Lucid and Veris Health commercialization efforts.
  • They have implemented a workforce reduction of approximately 20%, product portfolio streamlining, and other cost-cutting measures which seek to lower quarterly cash burn by at least 25%.
  • Lucid plans to pause further development of the EsoCure Esophageal Ablation device and delay completion of the EsoGuard BE-2 study to the second half of 2023.
  • Veris plans to delay the development and regulatory submission of the implantable physiologic monitor to the second half of 2023
  • PAVmed will indefinitely pause or halt all other product development activities, including CarpX, PortIO, and NextFlo, and pursue additional cost-cutting initiatives, including not paying annual cash bonuses.
  • Price Action: PAVM shares closed 8.10% higher at $0.6326, and LUCD 20% higher at $1.56 on Tuesday.
  • 帕夫迈 (納斯達克股份有限公司), 其多數擁有的子公司 清醒診斷公司 (納斯達克:LUCD), 和 韋里斯健康公司 提供了戰略業務更新，概述了近期戰略優先事項和資源重新分配。
  • 這些公司將優先考慮近期清醒和 Veris 健康的商業化工作。
  • 他們實施了人力減少約 20％，簡化了產品組合以及其他降低成本的措施，這些措施旨在減少每季度現金消耗至少 25％。
  • 清醒計劃暫停 eSocure 食管消融裝置的進一步開發，並將 EoGuard BE-2 研究的完成延遲至 2023 年下半年。
  • Veris 計劃將植入式生理監測器的開發和監管提交延遲到 2023 年下半年
  • PavMed 將無限期暫停或停止所有其他產品開發活動，包括 CarPx、Portio 和 NextFlo，並進行額外的成本削減計劃，包括不支付年度現金獎金。
  • 價格行動： 百富集團股份上漲 8.10%，報 0.6326 美元，周二收盤 20%，報 1.56 美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論